Pfizer Inc. (NYSE:PFE) Shares Sold by Asset Planning Inc

Asset Planning Inc trimmed its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 68.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,878 shares of the biopharmaceutical company's stock after selling 19,535 shares during the quarter. Asset Planning Inc's holdings in Pfizer were worth $225,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of PFE. William B. Walkup & Associates Inc. grew its position in Pfizer by 1.2% in the 4th quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company's stock valued at $1,044,000 after buying an additional 454 shares during the last quarter. Members Trust Co grew its position in Pfizer by 2.1% in the 1st quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock valued at $587,000 after buying an additional 467 shares during the last quarter. Sutton Place Investors LLC grew its position in Pfizer by 5.6% in the 1st quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company's stock valued at $224,000 after buying an additional 472 shares during the last quarter. Bellevue Group AG grew its position in Pfizer by 0.3% in the 4th quarter. Bellevue Group AG now owns 141,560 shares of the biopharmaceutical company's stock valued at $3,756,000 after buying an additional 485 shares during the last quarter. Finally, Gould Capital LLC grew its position in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 493 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on PFE. Morgan Stanley lifted their price objective on shares of Pfizer from $31.00 to $32.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 30th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective on the stock. UBS Group boosted their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Jefferies Financial Group boosted their target price on shares of Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research report on Wednesday, May 21st. Finally, The Goldman Sachs Group boosted their target price on shares of Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $28.28.

Pfizer Price Performance

Pfizer stock opened at $23.49 on Friday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.32. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. The firm's 50-day simple moving average is $24.36 and its 200 day simple moving average is $24.58. The firm has a market capitalization of $133.55 billion, a PE ratio of 17.02, a P/E/G ratio of 0.84 and a beta of 0.52.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business's revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.82 EPS. On average, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.3%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio is 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.